 EMERYVILLE, Calif.--BUSINESS WIRE--Adamas Pharmaceuticals, Inc. Nasdaq: ADMS, a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the U.S. Food and Drug Administration FDA for a supplemental New Drug Application for GOCOVRI amantadine extended release capsules, gaining a second indication for the product. GOCOVRI is now approved as an adjunc 